Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 197

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local–Regionally Advanced Head and Neck Squamous Cell Carcinoma

Open access
Wise-Draper, Trisha M., Gulati, Shuchi, Palackdharry, Sarah, Hinrichs, Benjamin H., Worden, Francis P., Old, Matthew O., Dunlap, Neal E., Kaczmar, John M., Patil, Yash, Riaz, Muhammed Kashif, Tang, Alice, Mark, Jonathan, Zender, Chad, Gillenwater, Ann M., Bell, Diana, Kurtzweil, Nicky, Mathews, Maria, Allen, Casey L., Mierzwa, Michelle L., Casper, Keith, Jandarov, Roman, Medvedovic, Mario, Lee, J. Jack, Harun, Nusrat, Takiar, Vinita, Gillison, Maura · 2022 · Clinical Cancer Research

Abstract

Purpose: Patients with resected, local–regionally advanced, head and neck squamous cell carcinoma (HNSCC) have a one-year disease-free survival (DFS) rate of 65%–69% despite adjuvant (chemo)radiotherapy. Neoadjuvant PD-1 immune-checkpoint blockade (ICB) has demonstrated clinical activity, but biomarkers of response and effect on survival remain unclear. Patients and Methods: Eligible patients had resectable squamous cell carcinoma of the oral cavity, larynx, hypopharynx, or oropharynx (p16-negative) and clinical stage T3-T4 and/or two or more nodal metastases or clinical extracapsular nodal extension (ENE). Patients received neoadjuvant pembrolizumab 200 mg 1–3 weeks prior to surgery, were stratified by absence (intermediate-risk) or presence (high-risk) of positive margins and/or ENE, and received adjuvant radiotherapy (60–66 Gy) and concurrent pembrolizumab (every 3 weeks × 6 doses). Patients with high-risk HNSCC also received weekly, concurrent cisplatin (40 mg/m2). Primary outcome was one-year DFS. Secondary endpoints were one-year overall survival (OS) and pathologic response (PR). Safety was evaluated with CTCAE v5.0. Results: From February 2016 to October 2020, 92 patients enrolled. The median age was 59 years (range, 27–80), 30% were female, 86% had stage T3–T4, and 69% had ≥N2. At a median follow-up of 28 months, one-year DFS was 97% (95% CI, 71%–90%) in the intermediate-risk group and 66% (95% CI, 55%–84%) in the high-risk group. Patients with a PR had significantly improved one-year DFS relative to patients without response (93% vs. 72%, hazard ratio 0.29; 95% CI, 11%–77%). No new safety signals were identified. Conclusions: Neoadjuvant and adjuvant pembrolizumab increased one-year DFS rate in intermediate-risk, but not high-risk, HNSCC relative to historical control. PR to neoadjuvant ICB is a promising surrogate for DFS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-21-3351

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 197

Metadata

Authors
Wise-Draper, T. M., Gulati, S., Palackdharry, S., Hinrichs, B. H., Worden, F. P., Old, M. O., Dunlap, N. E., Kaczmar, J. M., Patil, Y., Riaz, M. K., Tang, A., Mark, J., Zender, C., Gillenwater, A. M., Bell, D., Kurtzweil, N., Mathews, M., Allen, C. L., Mierzwa, M. L., Casper, K., Jandarov, R., Medvedovic, M., Lee, J. J., Harun, N., Takiar, V., & Gillison, M.
Venue
Clinical Cancer Research
Published
2022-02-28
Volume
28
Issue
7
Pages
1345-1352
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W4220868504
Cited by
197
References
7
FWCI
28.93
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local–Regionally Advanced Head and Neck Squamous Cell Carcinoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-21-3351
The paper
Wise-Draper, T. M., Gulati, S., Palackdharry, S., Hinrichs, B. H., Worden, F. P., Old, M. O., Dunlap, N. E., Kaczmar, J. M., Patil, Y., Riaz, M. K., Tang, A., Mark, J., Zender, C., Gillenwater, A. M., Bell, D., Kurtzweil, N., Mathews, M., Allen, C. L., Mierzwa, M. L., . . . Gillison, M. (2022). Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local–Regionally Advanced Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-21-3351

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.